AbbVie In Hot Seat Over HCV Drugs' Serious Liver Injury Risk
This article was originally published in Scrip
Executive Summary
The US FDA's alert about liver failure and death in patients taking AbbVie Inc.'s hepatitis C fixed-dose combination therapies Viekira Pak and Technivie is a significant setback for a company that already is a distant second in the market behind Gilead Sciences Inc., and the agency's move clears the way for HCV newcomer Merck & Co. Inc.
You may also be interested in...
Deal Watch: Six Small Biopharma Mergers Reflect Recent Trend
M&A edition: Mergers by Century/Clade, Eliem/Tenet, Kintara/TuHURA, Aditxt/Appili, Onconova/Traws and Apotex/Searchlight follow other companies joining forces in a tight cash environment.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.